Young James Emmett

CFO James Young buys 6,000 shares of TLSI at $5.65; cluster of 2 other insiders bought within 14 days

CFO James Young purchased 6,000 shares (6.0K shares) of TriSalus Life Sciences at $5.65 on 2025-02-05, increasing his holdings from 24,000 shares to 30,000 shares (+25.0% vs pre-transaction holdings). This buy occurs within a cluster pattern—2 other insiders also purchased shares within the past 14 days—suggesting coordinated appetite from the insider team. The company reported revenue of $7,349,000.00 (latest quarter) with annual revenue growth of +49.3%, though it remains unprofitable with net income of $-2,399,000.00 for its most recent full fiscal year. The stock currently trades at $5.38, down -47.5% from its 52-week high of $10.25 but up +27.2% over the past 90 days, indicating recent recovery from earlier lows. The cluster buy pattern suggests management sees value at current levels despite the company's ongoing losses.

CFO James Emmett Young buys 24,000 TLSI shares at $5.40; 2 other insiders bought within 14 days as stock trades -52.3% from 52-week high.

James Emmett Young, CFO of TriSalus Life Sciences, purchased 24,000 shares at $5.40 on 2025-01-27, representing his first recorded holding and occurring as the stock trades at $4.89, down 52.3% from its 52-week high of $10.25. This buy clusters with 2 other insider purchases within the past 14 days, suggesting coordinated accumulation during a period of significant valuation compression. The company reported $7.3M in revenue (latest quarter) with $-2.4M net income and remains unprofitable on a full-year basis, yet has achieved 49.3% annual revenue growth, creating a tension between operational momentum and near-term profitability that may explain insider activity at depressed prices. Investors should monitor whether this cluster signals confidence in an eventual turnaround or reflects opportunistic accumulation at suppressed valuations following the sharp drawdown.